Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple attack: radiation, immunotherapy, and chemo take on tough breast cancer

NCT ID NCT06627712

Recruiting now Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Feb 01, 2026 · Last updated May 07, 2026 · Updated 11 times

Summary

This study tests whether adding targeted radiation (SBRT) to standard chemotherapy and immunotherapy can improve outcomes for people with early-stage triple-negative breast cancer (TNBC). TNBC is a hard-to-treat type of breast cancer with fewer treatment options. The trial will enroll 318 participants to see if this combination leads to a higher rate of complete tumor disappearance before surgery. The goal is to find a more effective neoadjuvant (pre-surgery) treatment for this aggressive cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China Hospital, Sichuan University

    RECRUITING

    Sichuan, Chengdu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

TNBC, TRIPLE NEGATIVE BREAST CANCER